Back to search

Aristotle University Of Thessaloniki (AUTH)

Μελέτη μοριακών δεικτών βλαστικών κυττάρων στο γυναικολογικό καρκίνο

Abstract

dc:description

The cancer stem cell hypothesis provides an attractive cellular mechanism to account for thetherapeutic refractoriness and the heterogeneity of most solid tumors. Cancer stem-like cells, the raresubpopulation of cells sustaining solid tumours, share important properties with pluripotent/multipotent stem cells. Both types of cells show self-renewal capacities, a variable potential formultilineage differentiation as well as invasiveness; thus, it has been suggested that a series ofembryonic genes, such as OCT4 and NANOG genes, may be reactivated or exhibit aberrant expressionpatterns in cancer.OCT4 and NANOG genes are precious transcription factors, involved in maintaining the stem andpluripotent states of a cell through transcriptional regulation; expression of these genes has previouslybeen demonstrated in various types of cancer and cancer cell lines. Importantly multiple OCT4- andNANOG- related pseudogenes have been identified, some of which are expressed in adult humantissues, while reporting on human “OCT4” as a stemness factor may be misleading; two isoforms, withdivergent biological functions, are generated by this gene. The actual stemness factor is OCT4A, whilethe other isoform, OCT4B, is a protein of as yet unknown function.The aim of this study is to validly investigate OCT4 isoforms and NANOG expression in ovarian andendometrial carcinomas. In parallel, we, indirectly, enquire into a putative role of OCT4B inoncogenesis; the minor allele (G) of the single nucleotide polymorphism rs3130932, locating in theOCT4B translation initiation codon, is expected to hamper OCT4B expression in homozygotesindividuals. A case–control association study was conducted for validating the GG genotype as a riskfactor for tumour development.Materials and Methods79 archival specimens were included in the gene expression study, namely 46 ovarian tumors (18serous borderline and 28 serous carcinomas), 24 endometrial carcinomas (10 grade I, 12 grade II and 2grade III) as well as 9 adjacent morphologically normal tissue areas (5 ovarian and 4 endometrial).Tissue microarrays (TMAs) were constructed and multiple cores (diameter 1.5mm) per tumor wereused. OCT4A/ OCT4B and NANOG expression was assessed on RNA that was extracted from TMAcore sections. Specific RT-PCR protocols were designed for the corresponding mRNA targets avoidingany known pseudogene matches. During standardization of the assays, a seminoma tumor was used ascontrol for OCT4A and NANOG, while peripheral blood mononuclear cell samples were used ascontrols for OCT4B. Anti-OCT4A (monoclonal, SC-5279) and anti-OCT4B (polyclonal, SC-25401)antibodies were used for immunohistochemical evaluation. Both cytoplasmic and nuclear positivity oftumor cells were evaluated and compared with normal tissue areas; focusing on OCT4A , sampleswere considered positive when there was medium and/or strong staining in >10% of tumor cells. Withregard to the case–control association study, blood samples were collected from 100 female patientswith, previously diagnosed, ovarian cancer and from 324 age-matched and sex-matched healthyindividuals. DNA was tested by restriction fragment length polymorphism-PCR for the presence ofrs3130932. Statistical association studies were carried out to investigate any associationbetween hOCT4 genotypes and the onset of cancer.ResultsRT-PCR study: OCT4A specific transcripts were detected in 29/70 cancerous samples as well as inone adjacent noncancerous tissue; this sample, although morphologically normal, adjoined to amalignant serous tumor. OCT4B specific transcripts were detected in 19 samples, distinctly cancerous.NANOG specific transcripts were detected in, almost, all the samples tested (cancerous andnoncancerous). Importantly OCT4A/ OCT4B/ NANOG specific transcripts were detected in very lowrelative amounts, as compared to endogenous controls.OCT4A and, especially, OCT4B transcripts were observed more often in ovarian than in endometrialtumors (p=0.0283 and p=0.0025, respectively).OCT4A and OCT4B mRNA expression correlated well with each other (p<0.0001) in the samplestested. Simultaneous OCT4A and OCT4B expression was not observed in normal samples but it wasstrongly associated with ovarian serous carcinomas (11/28 [39.3%], p=0.0044), while it was alsopresent in 3/18 (16.6%) ovarian borderline tumors and in 1/24 (4.2%) endometrial carcinomas, a gradeIII tumor.Immunohistochemistry study:Except for one serous carcinoma, 78/79 specimens tested were negativefor nuclear OCT4A. By contrast, cytoplasmic staining for OCT4B was observed in both cancerous and normal tissueelements in 76/79 cases. Nuclear positivity for OCT4B was observed in 15/46 ovarian, 6/24endometrial tumors and 3/9 adjacent noncancerous tissues.Case–control association study: Genotypic and allelic statistical analyses led to no significant case–control differences at a P value of less than 0.05 in ovarian cancer.ConclusionsLow OCT4A and OCT4B mRNA expression levels may be detected mainly in malignant ovariantumors and high grade endometrial carcinomas, reflecting the presence of a distinct cancer stem cellpopulation within the tumor. The simultaneous mRNA expression of both molecules seems to beassociated with the degree of malignancy. No correlation was observed between mRNA expression andimmunohistochemistry results. OCT4A protein was not detected in tumors expressing OCT4Atranscripts, likely, due to post-transcriptional/post-translational modifications. Importantly, sc-5279 andsc-25401 anti-OCT4 antibodies may, as well, detect pseudogene protein derivatives or OCT4-unrelatedpeptides, respectively.Low NANOG mRNA expression was detected in nearly all the samples examined, both cancerous andnon-cancerous. This intriguing expression pattern has recently been validated, reflecting the presenceof distinct, scarce populations of pluripotent stem cells in adult tissues and of cancer stem cells insomatic cancer, respectively. Of note, it was recently documented that stemness in human somaticcancer is mainly modulated via NANOGP8 protein, instead of the, previously considered, NANOG.The GG genotype in SNP rs3130932, hampering the expression of OCT4B-265 and OCT4B1 proteins,is not associated with increased/decreased ovarian cancer risk in individuals.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papamichos, Spyros
  • Παπαμίχος, Σπύρος

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38090

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papamichos, Spyros; Παπαμίχος, Σπύρος. Μελέτη μοριακών δεικτών βλαστικών κυττάρων στο γυναικολογικό καρκίνο. Aristotle University Of Thessaloniki (AUTH), 2013. http://hdl.handle.net/10442/hedi/38090